Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis

Inclusion Criteria: * Aged 18 to 75 years old, regardless of sex. * Diagnosed with bronchiectasis confirmed by High-Resolution Computed Tomography (HRCT) scan. * Bronchiectasis is currently in the stable phase. * Experienced at least one acute exacerbation of bronchiectasis within the previous 12 months. * Diagnosed with the Traditional Chinese Medicine (TCM) syndrome of "Phlegm-Heat Obstructing the Lungs". * Able to understand the study protocol and voluntarily sign the informed consent form. Exclusion Criteria: * Allergic to any ingredients of the investigational drug or placebo. * Comorbid with other severe systemic diseases (e.g., coronary heart disease, stroke, severe hypertension \[systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg\], active gastric ulcer, uncontrolled diabetes \[fasting venous blood glucose ≥ 10 mmol/L\], malignant tumors, abnormal liver or kidney function \[AST, ALT, or GGT \> 2 times the upper limit of normal; or serum creatinine \> 2 times the upper limit of normal\]) or psychiatric disorders. * Comorbid with asthma, allergic bronchopulmonary aspergillosis (ABPA), or active pulmonary tuberculosis. * Comorbid with chronic obstructive pulmonary disease (COPD) and presenting COPD as the primary clinical manifestation (as judged by the investigator). * Use of inhaled, oral, or intravenous antibiotics within 4 weeks prior to enrollment. * Type 2 respiratory failure requiring long-term non-invasive mechanical ventilation or oxygen therapy (\> 10 hours/d…